FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Trump administration directs federal health agencies to pause communications
Amid a deluge of executive actions, the Trump administration has asked federal health agencies to pause external ...
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
FDA proposes mandatory front-of-package nutrition labels to combat spike in chronic diseases
The U.S. Food and Drug Administration (FDA) is demanding increased, in-your-face food transparency when it comes to nutrition ...
Food companies want to confuse consumers. The FDA must push back.
Food companies criticize the science supporting front-of-package labeling, delay public consultation periods, push for their ...
US FDA puts clinical hold on Atara's trials for cancer cell therapies
Atara Biotherapeutics said on Tuesday the U.S. health regulator had placed a clinical hold on its trials for cancer cell ...
FDA makes key decision on Zyn nicotine pouches
In a statement, the FDA said it has authorized the marketing and sale of Philip Morris International’s Zyn nicotine pouches.
STAT21h
Three former FDA officials: Here’s what Trump and his nominees need to know
The FDA is the leading science-based consumer protection agency in the world. Three former senior officials write about what ...
Managed Healthcare Executive1h
FDA Approves Spravato Nasal Spray as a Standalone Treatment for Major Depressive Disorder
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...
The National Law Review10h
FDA Proposes Front-of-Package Labeling Requirements
On 14 January 2024, the US Food and Drug Administration (FDA) issued a proposed rule to be published on 16 January, which, if ...